Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the systemic inflammation of acute alveolar hypoxia.
Alveolar hypoxia produces rapid systemic inflammation in rats. Several lines of evidence suggest that the inflammation is not initiated by low systemic tissue partial pressure of oxygen (Po(2)) but by a mediator released into the circulation by hypoxic alveolar macrophages. The mediator activates tissue mast cells to initiate inflammation. Monocyte chemoattractant protein-1/Chemokine (C-C motif) ligand 2 (MCP-1/CCL2) is rapidly released by hypoxic alveolar macrophages. This study investigated whether MCP-1 is the mediator of the systemic inflammation of alveolar hypoxia. Experiments in rats and in alveolar macrophages and peritoneal mast cells led to several results. (1) Alveolar hypoxia (10% O(2) breathing, 60 minutes) produced a rapid (5-minute) increase in plasma MCP-1 concentrations in conscious intact rats but not in alveolar macrophage-depleted rats. (2) Degranulation occurred when mast cells were immersed in the plasma of hypoxic intact rats but not in the plasma of alveolar macrophage-depleted rats. (3) MCP-1 added to normoxic rat plasma and the supernatant of normoxic alveolar macrophages produced a concentration-dependent degranulation of immersed mast cells. (4) MCP-1 applied to the mesentery of normoxic intact rats replicated the inflammation of alveolar hypoxia. (5) The CCR2b receptor antagonist RS-102895 prevented the mesenteric inflammation of alveolar hypoxia in intact rats. Additional data suggest that a cofactor constitutively generated in alveolar macrophages and present in normoxic body fluids is necessary for MCP-1 to activate mast cells at biologically relevant concentrations. We conclude that alveolar macrophage-borne MCP-1 is a key agent in the initiation of the systemic inflammation of alveolar hypoxia.
Chao
Jie
J
Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Donham
Paula
P
van Rooijen
Nico
N
Wood
John G
JG
Gonzalez
Norberto C
NC
D000818:Animals; D015550:Cell Degranulation / Q000276:immunology; D002478:Cells, Cultured; D018932:Chemokine CCL2 / Q000096:biosynthesis / Q000276:immunology*; D000860:Hypoxia / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D016676:Macrophages, Alveolar / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008407:Mast Cells / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D011650:Pulmonary Alveoli / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D054390:Receptors, CCR2 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism
C491766:Ccl2 protein, rat; D018932:Chemokine CCL2; D054390:Receptors, CCR2
Crit Care Med. 2005 Jun;33(6):1351-8
15942355
Cytokine Growth Factor Rev. 1996 Jun;7(1):47-64
8864354
Am J Respir Crit Care Med. 2001 Sep 1;164(5):826-30
11549540
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3652-6
8170963
J Biol Chem. 1995 May 19;270(20):11703-6
7744810
Environ Health Perspect. 2006 Mar;114(3):412-9
16507465
J Am Coll Cardiol. 2008 Aug 26;52(9):719-26
18718418
Lancet. 2003 Jun 7;361(9373):1967-74
12801752
Am J Physiol Lung Cell Mol Physiol. 2006 Jul;291(1):L102-10
16461432
Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2285-94
17208999
Immunology. 1995 Nov;86(3):434-40
8550082
Circulation. 2008 Apr 29;117(17):2270-8
18413499
Life Sci. 2006 Aug 22;79(13):1293-300
16712875
J Exp Med. 1992 Sep 1;176(3):781-6
1512541
Blood. 2000 Jul 1;96(1):34-40
10891427
Clin Diagn Lab Immunol. 2003 Sep;10(5):813-20
12965910
J Appl Physiol (1985). 1993 Apr;74(4):1994-2003
8514721
J Appl Physiol (1985). 1999 Nov;87(5):1734-40
10562616
Am J Physiol Lung Cell Mol Physiol. 2005 Jan;288(1):L3-15
15591040
J Immunol. 1995 Dec 15;155(12):5769-76
7499865
J Appl Physiol (1985). 2003 Jun;94(6):2323-9
12598489
Am J Respir Cell Mol Biol. 2001 Dec;25(6):780-7
11726405
Am J Physiol Lung Cell Mol Physiol. 2003 Feb;284(2):L360-7
12388372
Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L79-85
18469117
Am J Physiol Lung Cell Mol Physiol. 2007 Jul;293(1):L105-13
17416740
J Appl Physiol (1985). 2003 Jan;94(1):325-34
12391033
Chest. 2003 Aug;124(2):548-53
12907541
J Appl Physiol (1985). 2001 Sep;91(3):1160-7
11509511
J Appl Physiol (1985). 2003 Dec;95(6):2495-502
12949012
Ann Thorac Surg. 2002 Sep;74(3):899-905; discussion 905
12238858
Cardiovasc Res. 1996 Oct;32(4):699-708
8915188
Ann Hematol. 1995 May;70(5):251-8
7541256
Am J Physiol. 1993 Mar;264(3 Pt 2):R610-4
8457016
Am J Respir Cell Mol Biol. 2009 Nov;41(5):573-82
19244200
J Immunol Methods. 1994 Sep 14;174(1-2):83-93
8083541
Physiol Rev. 1997 Oct;77(4):1033-79
9354811
J Appl Physiol (1985). 2007 Oct;103(4):1386-94
17656628
Br J Pharmacol. 2003 Feb;138(4):698-706
12598424
COPD. 2008 Apr;5(2):133-8
18415812
Prostaglandins Leukot Essent Fatty Acids. 2008 Feb;78(2):137-46
18093816
Respir Res. 2005 Aug 01;6:87
16053532
J Appl Physiol (1985). 2005 Jul;99(1):290-7
15746296
Respir Res. 2009 Jun 22;10:54
19545431
J Appl Physiol (1985). 1999 Sep;87(3):873-81
10484552
J Appl Physiol (1985). 2000 Oct;89(4):1561-8
11007596
Am J Respir Cell Mol Biol. 1995 Oct;13(4):399-409
7546769